- Recommendation ID
- IPG628/1
- Question
NICE encourages further research into intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer. Research should include randomised controlled trials, which stratify patients by risk and give adequate follow-up. They should report frequency of adverse events, patientreported outcome measures, overall and disease-free survival and quality of life.
- Any explanatory notes
(if applicable) The evidence on the safety of intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer shows there are wellrecognised adverse events. Current evidence on its efficacy is limited in quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.
Source guidance details
- Comes from guidance
- Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer
- Number
- IPG628
- Date issued
- September 2018
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/08/2018 |